
Salost DR35 mg
Unimed Unihealth MFG. Ltd.
Established / FDA-Approved Uses Treatment and prevention of postmenopausal osteoporosis - Risedronate Sodium reduces the risk of vertebral and hip fractures in postmenopausal women.
Risedronate Sodium is used as part of a comprehensive treatment plan that may include adequate calcium and vitamin D intake, weight-bearing exercise, and lifestyle modification (smoking cessation, limiting alcohol) as advised by the physician.
| Indication | Regimen |
|---|---|
| Postmenopausal osteoporosis - treatment | 5 mg once daily, OR 35 mg once weekly, OR 150 mg once monthly |
| Postmenopausal osteoporosis - prevention | 5 mg once daily, OR 35 mg once weekly |
| Osteoporosis in men | 35 mg once weekly |
| Glucocorticoid-induced osteoporosis (prevention/treatment) | 5 mg once daily |
| Paget's disease of bone | 30 mg once daily for 2 months (retreatment may be considered after relapse, following physician re-evaluation) |
Risedronate Sodium tablets must be swallowed whole (not crushed or chewed) while the patient is in an upright position, taken:
Adequate calcium and vitamin D intake should be ensured as advised by the physician, though calcium/mineral supplements themselves must not be taken within 30 minutes of Risedronate Sodium (see Interaction).
Patients should seek medical attention for severe or persistent gastrointestinal symptoms, new hip/groin/thigh pain, or jaw pain/swelling while taking Risedronate Sodium.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.